Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE dexamphetamine for cocaine use disorder in methadone-treated patients
NL-OMON59489Phase 3Suspended
- Sponsor
- Parnassia Groep
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cocaine use disorder (CUD) comparing Sustained-release dexamphetamine with Placebo (2 arms). Primary endpoints: Days of cocaine abstinence during final 4 weeks of treatment and Good or improved overall health status. Started Mar 2026; status: suspended.
02
Drugs
dextroamphetamine
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NL-OMON59489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59489.